Cargando…
Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond
The coronavirus disease 2019 (COVID-19) pandemic has led to the deprioritization of non-emergency services, such as oral food challenges and the initiation of oral immunotherapy (OIT) for food-allergic children. Recent studies have suggested that home-based peanut OIT could be a safe and effective o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974914/ https://www.ncbi.nlm.nih.gov/pubmed/35387028 http://dx.doi.org/10.3389/falgy.2021.725165 |
_version_ | 1784680299691507712 |
---|---|
author | Chua, Gilbert T. Chan, Edmond S. Soller, Lianne Cook, Victoria E. Vander Leek, Timothy K. Mak, Raymond |
author_facet | Chua, Gilbert T. Chan, Edmond S. Soller, Lianne Cook, Victoria E. Vander Leek, Timothy K. Mak, Raymond |
author_sort | Chua, Gilbert T. |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic has led to the deprioritization of non-emergency services, such as oral food challenges and the initiation of oral immunotherapy (OIT) for food-allergic children. Recent studies have suggested that home-based peanut OIT could be a safe and effective option for low-risk peanut-allergic children. In the period between September 1, 2020, and January 31, 2021, nine preschoolers with a history of mild allergic reactions to peanut underwent home-based peanut OIT. Eight of them (88.9%) completed the build-up phase at home in 11–28 weeks, tolerating a daily maintenance dose of 320 mg peanut protein. During the build-up, six patients (75.0%) reported urticaria, three (33.3%) reported gastrointestinal tract symptoms, and one (14.3%) reported oral pruritis. None of the patients developed anaphylaxis, required epinephrine, or attended emergency services related to OIT. One or two virtual follow-up visits were completed per patient during the build-up phase. Our case series shows that home-based OIT could be offered to the low-risk preschoolers during the COVID-19 pandemic when non-emergency services are limited and could be considered beyond the pandemic, especially for the families living in the rural or remote areas that may otherwise be unable to access OIT. |
format | Online Article Text |
id | pubmed-8974914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89749142022-04-05 Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond Chua, Gilbert T. Chan, Edmond S. Soller, Lianne Cook, Victoria E. Vander Leek, Timothy K. Mak, Raymond Front Allergy Allergy The coronavirus disease 2019 (COVID-19) pandemic has led to the deprioritization of non-emergency services, such as oral food challenges and the initiation of oral immunotherapy (OIT) for food-allergic children. Recent studies have suggested that home-based peanut OIT could be a safe and effective option for low-risk peanut-allergic children. In the period between September 1, 2020, and January 31, 2021, nine preschoolers with a history of mild allergic reactions to peanut underwent home-based peanut OIT. Eight of them (88.9%) completed the build-up phase at home in 11–28 weeks, tolerating a daily maintenance dose of 320 mg peanut protein. During the build-up, six patients (75.0%) reported urticaria, three (33.3%) reported gastrointestinal tract symptoms, and one (14.3%) reported oral pruritis. None of the patients developed anaphylaxis, required epinephrine, or attended emergency services related to OIT. One or two virtual follow-up visits were completed per patient during the build-up phase. Our case series shows that home-based OIT could be offered to the low-risk preschoolers during the COVID-19 pandemic when non-emergency services are limited and could be considered beyond the pandemic, especially for the families living in the rural or remote areas that may otherwise be unable to access OIT. Frontiers Media S.A. 2021-09-24 /pmc/articles/PMC8974914/ /pubmed/35387028 http://dx.doi.org/10.3389/falgy.2021.725165 Text en Copyright © 2021 Chua, Chan, Soller, Cook, Vander Leek and Mak. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Allergy Chua, Gilbert T. Chan, Edmond S. Soller, Lianne Cook, Victoria E. Vander Leek, Timothy K. Mak, Raymond Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond |
title | Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond |
title_full | Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond |
title_fullStr | Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond |
title_full_unstemmed | Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond |
title_short | Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond |
title_sort | home-based peanut oral immunotherapy for low-risk peanut-allergic preschoolers during the covid-19 pandemic and beyond |
topic | Allergy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974914/ https://www.ncbi.nlm.nih.gov/pubmed/35387028 http://dx.doi.org/10.3389/falgy.2021.725165 |
work_keys_str_mv | AT chuagilbertt homebasedpeanutoralimmunotherapyforlowriskpeanutallergicpreschoolersduringthecovid19pandemicandbeyond AT chanedmonds homebasedpeanutoralimmunotherapyforlowriskpeanutallergicpreschoolersduringthecovid19pandemicandbeyond AT sollerlianne homebasedpeanutoralimmunotherapyforlowriskpeanutallergicpreschoolersduringthecovid19pandemicandbeyond AT cookvictoriae homebasedpeanutoralimmunotherapyforlowriskpeanutallergicpreschoolersduringthecovid19pandemicandbeyond AT vanderleektimothyk homebasedpeanutoralimmunotherapyforlowriskpeanutallergicpreschoolersduringthecovid19pandemicandbeyond AT makraymond homebasedpeanutoralimmunotherapyforlowriskpeanutallergicpreschoolersduringthecovid19pandemicandbeyond |